BLX Stock Analysis: Bladex | NYSE
Banks - Regional | NYSE, USA | Market Cap: 2.067m USD | 12M Return: 28.3% | PAP169941328 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.90M
EPS Trend: 91.6%
Rev. Trend: -10.2%
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bladex Inc. (NYSE: BLX) is a Panama-based multinational bank that specializes in financing foreign trade and supporting economic integration across Latin America and the Caribbean. The company operates through two main segments: Commercial and Treasury, and accepts deposits while serving financial institutions, corporations, sovereigns, and state-owned entities. It was founded in 1975 and is headquartered in Panama City.
The bank offers a broad suite of trade-related products, including bilateral short- and medium-term loans, structured and syndicated credits, loan commitments, letters of credit, guarantees, co-financing arrangements, factoring, vendor financing, and financial leasing. It also conducts investment management activities, holding securities at fair value through other comprehensive income and at amortized cost. The company was formerly known as Banco Latinoamericano de Comercio Exterior, S.A., and rebranded to Bladex Inc. in June 2026.
Bladex operates within the GICS Specialized Finance sub-industry, a niche segment of the financials sector that focuses on trade finance and cross-border lending. As a mid-cap stock with a market capitalization of approximately $2.04 billion USD, it has been listed on the NYSE since its 1992 IPO, providing investors with exposure to Latin American trade flows and regional banking activity.
- Latin American trade volumes drive Commercial segment loan growth
- Net interest margins expand on higher LatAm benchmark rates
- Credit quality deteriorates as sovereign and corporate defaults rise
| Net Income: 233.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.61 > 1.0 |
| NWC/Revenue: -941.9% < 20% (prev -711.9%; Δ -230.0% < -1%) |
| CFO/TA 0.03 > 3% & CFO 393.1m > Net Income 233.9m |
| Net Debt (2.27b) to EBITDA (239.9m): 9.48 < 3 |
| Current Ratio: 0.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.6m) vs 12m ago 1.71% < -2% |
| Gross Margin: 54.20% > 18% (prev 35.60%; Δ 18.61% > 0.5%) |
| Asset Turnover: 4.47% > 50% (prev 6.46%; Δ -1.99% > 0%) |
| Interest Coverage Ratio: 0.39 > 6 (EBIT TTM 233.9m / Interest Expense TTM 603.8m) |
| A: -0.40 (Total Current Assets 1.89b - Total Current Liabilities 7.59b) / Total Assets 14.4b |
| B: 0.07 (Retained Earnings 949.2m / Total Assets 14.4b) |
| C: 0.02 (EBIT TTM 233.9m / Avg Total Assets 13.6b) |
| D: 0.14 (Book Value of Equity 1.76b / Total Liabilities 12.7b) |
| Altman-Z'' = -2.12 = D |
| DSRI: 2.03 (Receivables 158.2m/105.2m, Revenue 605.6m/818.5m) |
| GMI: 0.66 (GM 35.60% / 54.20%) |
| AQI: 1.05 (AQ_t 0.87 / AQ_t-1 0.83) |
| SGI: 0.74 (Revenue 605.6m / 818.5m) |
| TATA: -0.01 (NI 233.9m - CFO 393.1m) / TA 14.4b) |
| Beneish M = -2.65 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at USD 54.78 with a total of 222,382 shares traded. Over the past week, the price has changed by -0.78%, over one month by -2.75%, over three months by -2.46% and over the past year by +28.28%.
Current recommended Stop Loss: 53.10 (which is 3.1% or 1.3 ATR below the current price).
Bladex has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy BLX.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 65.9 | 20.3% |
P/E Trailing = 9.0396
P/E Forward = 8.3752
P/S = 6.211
P/B = 1.1865
P/EG = 1.7665
Revenue TTM = 605.6m USD
EBIT TTM = 233.9m USD
EBITDA TTM = 239.9m USD
Long Term Debt = 4.15b USD (from longTermDebt, last quarter)
Short Term Debt = 276.9m USD (from shortTermDebt, last quarter)
Debt = 4.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 19.3m
Net Debt = 2.27b USD (calculated: Debt 4.46b - CCE 2.19b)
Enterprise Value = 4.34b USD (2.07b + Debt 4.46b - CCE 2.19b)
Interest Coverage Ratio = 0.39 (Ebit TTM 233.9m / Interest Expense TTM 603.8m)
EV/FCF = 11.09x (Enterprise Value 4.34b / FCF TTM 391.4m)
FCF Yield = 9.02% (FCF TTM 391.4m / Enterprise Value 4.34b)
FCF Margin = 64.62% (FCF TTM 391.4m / Revenue TTM 605.6m)
Net Margin = 38.61% (Net Income TTM 233.9m / Revenue TTM 605.6m)
Gross Margin = 54.20% ((Revenue TTM 605.6m - Cost of Revenue TTM 277.4m) / Revenue TTM)
Gross Margin QoQ = 40.13% (prev 94.34%)
Tobins Q-Ratio = 0.30 (Enterprise Value 4.34b / Total Assets 14.4b)
Interest Expense / Debt = 13.53% (Interest Expense 603.8m / Debt 4.46b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 184.8m (EBIT 233.9m * (1 - 21.00%))
Current Ratio = 0.25 (Total Current Assets 1.89b / Total Current Liabilities 7.59b)
Debt / Equity = 2.54 (Debt 4.46b / totalStockholderEquity, last quarter 1.76b)
Debt / EBITDA = 9.48 (Net Debt 2.27b / EBITDA 239.9m)
Debt / FCF = 5.81 (Net Debt 2.27b / FCF TTM 391.4m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.73% (Net Income 233.9m / Total Assets 14.4b)
RoE = 13.78% (Net Income TTM 233.9m / Total Stockholder Equity 1.70b)
RoCE = 4.00% (EBIT 233.9m / Capital Employed (Equity 1.70b + L.T.Debt 4.15b))
RoIC = 1.28% (NOPAT 184.8m / Invested Capital 14.4b)
WACC = 9.63% (E(2.07b)/V(6.53b) * Re(7.35%) + D(4.46b)/V(6.53b) * Rd(13.53%) * (1-Tc(0.21)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.65 | Cagr: 1.16%
[DCF] Terminal Value 73.93% ; FCFF base≈290.9m ; Y1≈333.4m ; Y5≈490.7m
[DCF] Fair Price = 124.7 (EV 6.02b - Net Debt 2.27b = Equity 3.75b / Shares 30.1m; r=9.63% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 91.64 | EPS CAGR: 13.53% | SUE: N/A | # QB: 0
Revenue Correlation: -10.17 | Revenue CAGR: -1.60% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=6.47 | Chg30d=-5.61% | Revisions=+25% | GrowthEPS=+6.0% | GrowthRev=+10.5%
EPS next Year (2027-12-31): EPS=7.04 | Chg30d=-0.21% | Revisions=+25% | GrowthEPS=+8.7% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: +40% (up=2, down=0)